# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY

A. 510(k) Number: k072032   
B. Purpose for Submission: New Device   
C. Measurand: IgG oxidized low-density lipoprotein (oxLDL) beta2-glycoprotein 1 complex (antioxidized LDL/β2GPI) antibodies in human serum.   
D. Type of Test: Semiquantitative ELISA   
E. Applicant: Corgenix, Inc.   
F. Proprietary and Established Names: IgG Anti-AtherOx™ Test Kit

# G. Regulatory Information:

1. Regulation section: 21 CFR 866.5660 Multiple autoantibodies immunological test system   
2. Classification: Class II   
3. Product code: MSV - system, test, antibodies, β2-glycoprotein 1 (β2-GP1)   
4. Panel: 82 - Immunology

# H. Intended Use:

1. Intended use(s): An enzyme-linked immunoassay (ELISA) for the detection of IgG antibodies to complexes formed by oxidized low-density lipoprotein (oxLDL) with $\beta _ { 2 } .$ - glycoprotein I $( \mathsf { \beta } _ { 2 } \mathrm { { G P I } ) }$ in individuals with systemic lupus erythematosus (SLE) and lupus-like disorders (antiphospholipid syndrome).   
2. Indication(s) for use: Same as Intended Use   
3. Special conditions for use statement(s): For prescription use only   
4. Special instrument requirements: Microplate reader capable of measuring OD $4 5 0 \mathrm { n m }$ .

# I. Device Description:

Each device contains the following: stabilized oxLDL-β2GPI antigen (human) coated microwell strips, with frame, sample diluent, IgG calibrator sera (human) (1-high, 2- moderate, 3-low), IgG positive control serum (human), IgG normal control serum (human), IgG anti-human (goat) HRP-conjugated antibody solution, one-component substrate (TMB and $\mathrm { H } _ { 2 } \mathrm { O } _ { 2 }$ ), stopping solution, and wash concentrate.

J. Substantial Equivalence Information:

1. Predicate device name(s):

# REAADS Anti-Cardiolipin IgG/IgM Semi-Quantitative kit

2. Predicate K number(s): k022992

3. Comparison with predicate:

<table><tr><td rowspan=1 colspan=3>Similarities</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Device</td><td rowspan=1 colspan=1>Predicate</td></tr><tr><td rowspan=1 colspan=1>Indications forUse</td><td rowspan=1 colspan=1>For individuals with SLE andlupus-like disorders (anti-phospholipid syndrome)</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Specimen Type</td><td rowspan=1 colspan=1>Serum</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Technology</td><td rowspan=1 colspan=1>ELISA</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Assay format</td><td rowspan=1 colspan=1>Semi-quantitative</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Solid phase</td><td rowspan=1 colspan=1>Coated polystyrene microwellplates</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Enzyme-conjugate</td><td rowspan=1 colspan=1>Horseradish peroxidaseconjugated to goat anti-humanIgG</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Substrate</td><td rowspan=1 colspan=1>TMB chromogen</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Resultsdetermination</td><td rowspan=1 colspan=1>Multipoint calibration curve</td><td rowspan=1 colspan=1>Multipoint calibration curve(or single point calibrator)</td></tr></table>

<table><tr><td rowspan=1 colspan=3>Differences</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Device</td><td rowspan=1 colspan=1>Predicate</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>An enzyme-linked immuno-assay (ELISA) for thedetection of IgG antibodies tocomplexes formed by oxidizedlow-density lipoprotein(oxLDL) with β2-glycoproteinI (β2GPI) in individuals withsystemic lupus erythematosus(SLE) and lupus-like disorders(anti-phospholipid syndrome).</td><td rowspan=1 colspan=1>For the detection and semi-quantitation of anti-cardiolipin antibodies inindividuals with systemiclupus erythematosus (SLE)and lupus-like disorders(anti-phospholipidsyndrome).</td></tr><tr><td rowspan=1 colspan=1>Analyte</td><td rowspan=1 colspan=1>IgG anti-oxidized LDL/β2GPIantibodies</td><td rowspan=1 colspan=1>IgG anti-cardiolipinantibodies</td></tr><tr><td rowspan=1 colspan=1>Capture antigen</td><td rowspan=1 colspan=1>OxLDL/β2-GPI complexes</td><td rowspan=1 colspan=1>Purified cardiolipin</td></tr><tr><td rowspan=1 colspan=1>Positive &amp;negative controls</td><td rowspan=1 colspan=1>Dilute 1:100</td><td rowspan=1 colspan=1>Ready to use</td></tr><tr><td rowspan=1 colspan=1>Assay time</td><td rowspan=1 colspan=1>150 min at RT</td><td rowspan=1 colspan=1>40 min at RT</td></tr><tr><td rowspan=1 colspan=1>Quantitationrange</td><td rowspan=1 colspan=1>10-100 G Units</td><td rowspan=1 colspan=1>0-100 GPL Units</td></tr><tr><td rowspan=1 colspan=1>Sample type anddilution</td><td rowspan=1 colspan=1>Human serum at 1:100</td><td rowspan=1 colspan=1>1:50</td></tr></table>

# K. Standard/Guidance Document Referenced (if applicable):

EP5-A2 Evaluation of Precision Performance of Quantitative Measurement Methods EP6-A Evaluation of the Linearity of Quantitative Measurement Procedures: A Statistical Approach; Approved Guideline EP17-A Protocols for Determination of Limits of Quantitation; Approved Guideline

# L. Test Principle:

Diluted serum samples, calibrator(s), and controls are incubated in microwells coated with the oxLDL- $\cdot \beta _ { 2 } \mathrm { G P I }$ complex. Incubation allows the IgG anti-oxLDL- $\cdot \beta _ { 2 } \mathrm { G P I }$ antibody present in the samples to react with the immobilized antigen complex. After the removal of unbound serum proteins by washing, anti-human IgG antibodies, labeled with horseradish peroxidase (HRP), are added forming complexes with the bound IgG anti-oxLDL- $\cdot \beta _ { 2 } \mathrm { G P I }$ antibody. Following another washing step, the bound enzyme-antibody conjugate is assayed by the addition of a solution containing tetramethylbenzidine (TMB) and hydrogen peroxide $\left( \mathrm { H } _ { 2 } \mathrm { O } _ { 2 } \right)$ as the chromogenic substrate. Color develops in the wells at an intensity proportional to the serum concentration of IgG anti-oxLDL- $\cdot \beta _ { 2 } \mathrm { G P I }$ antibody. Results are obtained by reading the OD (optical density or absorbance) of each well in a spectrophotometer. Calibrator sera are provided, with the $\mathrm { I g G }$ anti-oxLDL- $\cdot \beta _ { 2 } \mathrm { G P I }$ antibody concentration expressed in G Units. A log-log regression analysis is performed with calibrator values plotted against calibrator mean ODs. Controls and patient results are determined from the calibration curve.

# M. Performance Characteristics (if/when applicable):

1. Analytical performance:

a. Precision/Reproducibility: Precision: Serum samples with concentrations spanning the range of the assay were tested in the Corgenix laboratory by 2 operators in duplicate on each of 20 days over 30 calendar days. One reagent lot was tested, and assays were calibrated each day.

<table><tr><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>Mean Conc.(G Units)</td><td rowspan=1 colspan=1>Inter-assayPrecision (%CV)</td><td rowspan=1 colspan=1>Within-laboratoryPrecision (%CV)</td></tr><tr><td rowspan=1 colspan=1>Low</td><td rowspan=1 colspan=1>9.6</td><td rowspan=1 colspan=1>3%</td><td rowspan=1 colspan=1>13%</td></tr><tr><td rowspan=1 colspan=1>Med-Low</td><td rowspan=1 colspan=1>20.2</td><td rowspan=1 colspan=1>4%</td><td rowspan=1 colspan=1>12%</td></tr><tr><td rowspan=1 colspan=1>Med</td><td rowspan=1 colspan=1>28.1</td><td rowspan=1 colspan=1>7%</td><td rowspan=1 colspan=1>13%</td></tr><tr><td rowspan=1 colspan=1>Med-High</td><td rowspan=1 colspan=1>38.4</td><td rowspan=1 colspan=1>5%</td><td rowspan=1 colspan=1>12%</td></tr><tr><td rowspan=1 colspan=1>High</td><td rowspan=1 colspan=1>76.8</td><td rowspan=1 colspan=1>4%</td><td rowspan=1 colspan=1>10%</td></tr></table>

Reproducibility: Three operators at one site ran three clinical samples (low, medium, and high) over four consecutive days. The medium and high samples were run in triplicate and the low was run in quadruplicate. Results were determined from 48 measurements for the low sample and 36 for the medium and high sample.

<table><tr><td rowspan=2 colspan=1></td><td rowspan=1 colspan=3>Samples</td></tr><tr><td rowspan=1 colspan=1>Low</td><td rowspan=1 colspan=1>Medium</td><td rowspan=1 colspan=1>High</td></tr><tr><td rowspan=1 colspan=1>Mean (G Units)</td><td rowspan=1 colspan=1>19</td><td rowspan=1 colspan=1>48</td><td rowspan=1 colspan=1>94</td></tr><tr><td rowspan=1 colspan=1>Intra-assay %CV</td><td rowspan=1 colspan=1>4%</td><td rowspan=1 colspan=1>1%</td><td rowspan=1 colspan=1>2%</td></tr></table>

b. Linearity/assay reportable range:

Linearity: Independently duplicate dilutions of a strongly-positive sample, mixed at various fixed ratios with an IgG-depleted pooled serum, were prepared to produce 11 evenly-spaced concentrations that were predicted to extend past the linear range of the assay. Acceptance criterion was set at $\leq 5$ G units between predicted and recovered values. Evaluation of the data indicated that the linear range of the assay was $1 0 - 1 0 0 \mathrm { G }$ units.

c. Traceability, Stability, Expected values (controls, calibrators, or methods): No recognized reference material for IgG anti-oxLDL- $\cdot \beta _ { 2 } \mathrm { G P I }$ . The results are reported in arbitrary units.

Controls: The standards are prepared in-house and values are assigned during the development process. Positive and negative controls are prepared in-house.

Stability: Calibrators, controls, a sample diluent alone were used to assess the real-time stability of four kits every 4-6 months for a 24 month period. All kits were shown to be stable up to 12 months.

d. Detection limit:

Limit of Blank (LoB): Three serum samples were mixed and depleted of IgG using a protein G column. The IgG-depleted serum, four clinical samples, and a negative sample (sample diluent) were tested multiple times on two different plate readers. Ninety-two results were generated from the negative samples and 228 for the clinical samples. The frequency distribution were tabulated and the $9 5 ^ { \mathrm { t h } }$ percentile of the negative results at $6 . 1 \mathrm { G }$ units Limit of Detection (LoD): was defined the lowest level where $5 \%$ or fewer of the observed measurements are below the LoB based on a sample set showing non-Gaussian distribution. Since none of the results for the positive data set were at $7 . 0 \mathrm { G }$ units or below, so the LoD was set as $^ { 7 \mathrm { G } }$ units.

e. Analytical specificity:

Five clinical samples with the addition of increasing amounts of hemoglobin (to $5 0 0 \mathrm { m g / d L } )$ ), conjugated bilirubin (to $2 0 \mathrm { m g / d L }$ ), triglycerides (to $3 \ \mathrm { g / d L ) }$ , and rheumatoid factor (to 500 units $/ \mathrm { m l }$ ) were tested and showed that these levels had no effect on IgG Anti-AtherOx test kit results. However, it is recommended in the package insert that results obtained from grossly hemolyzed or lipemic specimens be interpreted with caution and that grossly lipemic samples can be clarified by centrifugation.

$f .$ Assay cut-off:

A cut-off value of $2 0 \mathrm { G }$ Units was established by testing 75 serum samples from healthy volunteers in duplicate. Values ranged from 3.5-17.8 G Units.

<table><tr><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>Range[G units]</td><td rowspan=1 colspan=1>Mean (Median)[G units]</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>95thpercentile</td><td rowspan=1 colspan=1>Mean + 3SD</td></tr><tr><td rowspan=1 colspan=1>75</td><td rowspan=1 colspan=1>3.5-17.7</td><td rowspan=1 colspan=1>8.8 (8.9)</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>13.8</td><td rowspan=1 colspan=1>17.7</td></tr></table>

2. Comparison studies:

a. Method comparison with predicate device: Serum samples from 143 Systemic lupus erythematosus (SLE), 99 rheumatoid arthritis and 205 normal healthy controls were tested for elevated IgG antiphospholipid antibody levels using the Corgenix IgG Anti-AtherOx and REAADS IgG anti-cardiolipin kits. Each group is summarized below:

SLE: Serum samples from 143 SLE patients (94 SLE with secondary APS, 19 SLE only and 30 with unknown APS status) were tested on the IgG AntiAthe $\mathbf { \nabla } \cdot \mathrm { O x } ^ { \mathrm { T M } }$ Test Kit ant the REAADS IgG Anti-Cardiolipin Test. The mean IgG anti-oxLDL- $\cdot \beta _ { 2 } \mathrm { G P I }$ antibody level of this group was determined to be 24.4 G Units. Of the SLE/APS subgroup, the mean IgG anti-oxLDL- $\beta _ { 2 } \mathrm { G P I }$ antibody level was $2 8 . 8 \mathrm { G }$ Units. Twenty five SLE/APS samples were positive when tested with the new device and 17 of these were also positive for anticardiolipin antibodies by the predicate device. Since the new and predicate devices detect different analytes, it is likely that some patients have one and not the other autoantibodies. Comparison with the predicate device for the SLE/APS group is shown below:

<table><tr><td rowspan=2 colspan=2>SLE/APS(N = 94)</td><td rowspan=1 colspan=3>REAADS IgG Anti-Cardiolipin</td></tr><tr><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=3 colspan=1>CorgenixIgG Anti-AtherOx</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>17</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>25</td></tr><tr><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>63</td><td rowspan=1 colspan=1>69</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>23</td><td rowspan=1 colspan=1>71</td><td rowspan=1 colspan=1>94</td></tr></table>

Positive Percent Agreement $= 7 3 . 9 \%$ (17/23) Negative Percent Agreement $= 8 8 . 7 \%$ (63/71) Overall $\%$ Agreement $= 8 5 . 1 \%$ (80/94)

The APS patients were then further analyzed according to their clinical history of APS manifestations: arterial thrombosis, venous thrombosis, or pregnancy morbidity. Results, including the SLE only group are summarized in the following tables:

<table><tr><td rowspan=2 colspan=2>Pregnancy Morbidity(N = 15)</td><td rowspan=1 colspan=3>REAADS IgG Anti-Cardiolipin</td></tr><tr><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=3 colspan=1>CorgenixIgG Anti-AtherOx</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>1</td></tr><tr><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>14</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>13</td><td rowspan=1 colspan=1>15</td></tr></table>

Positive Percent Agreement $= 0 \%$ $( 0 / 2 )$ Negative Percent Agreement $= 9 2 . 3 \%$ (12/13) Overall $\%$ Agreement $= 8 0 . 0 \%$ (12/15)

<table><tr><td rowspan=2 colspan=2>Arterial Thrombosis(N = 42)</td><td rowspan=1 colspan=3>REAADS IgG Anti-Cardiolipin</td></tr><tr><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=3 colspan=1>CorgenixIgG Anti-AtherOx</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>12</td></tr><tr><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>27</td><td rowspan=1 colspan=1>30</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>14</td><td rowspan=1 colspan=1>28</td><td rowspan=1 colspan=1>42</td></tr></table>

Positive Percent Agreement $= 7 8 . 6 \%$ (11/14) Negative Percent Agreement $= 9 6 . 4 \%$ (27/28) Overall $\%$ Agreement $= 9 0 . 5 \%$ (38/42)

<table><tr><td rowspan=2 colspan=2>Venous Thrombosis(N = 37)</td><td rowspan=1 colspan=3>REAADS IgG Anti-Cardiolipin</td></tr><tr><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=3 colspan=1>CorgenixIgG Anti-AtherOx</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>12</td></tr><tr><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>24</td><td rowspan=1 colspan=1>25</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>37</td></tr></table>

Positive Percent Agreement $= 8 5 . 7 \%$ (6/7) Negative Percent Agreement $= 8 0 . 0 \%$ (24/30) Overall $\%$ Agreement $= 8 1 . 1 \%$ (30/37)

For the 19 SLE patients without APS, the mean IgG anti-oxLDL- $\beta _ { 2 } \mathrm { G P I }$ antibody level was $1 2 . 0 \mathrm { G }$ Units. One sample was positive with the new device which was negative with the predicate.

<table><tr><td rowspan=2 colspan=2>SLE only(N = 19)</td><td rowspan=1 colspan=3>REAADS IgG Anti-Cardiolipin</td></tr><tr><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=3 colspan=1>CorgenixIgG Anti-AtherOx</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>1</td></tr><tr><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>18</td><td rowspan=1 colspan=1>18</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>19</td><td rowspan=1 colspan=1>19</td></tr></table>

Summary results for the SLE group are shown below:

<table><tr><td rowspan=2 colspan=2>SLE and SLE/APS(N = 143)</td><td rowspan=1 colspan=3>REAADS IgG Anti-Cardiolipin</td></tr><tr><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=3 colspan=1>CorgenixIgG Anti-AtherOx</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>19</td><td rowspan=1 colspan=1>16</td><td rowspan=1 colspan=1>35</td></tr><tr><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>102</td><td rowspan=1 colspan=1>108</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>25</td><td rowspan=1 colspan=1>118</td><td rowspan=1 colspan=1>143</td></tr></table>

Positive Percent Agreement $= 7 6 . 0 \%$ (19/25) Negative Percent Agreement $= 8 6 . 4 \%$ (102/118) Overall $\%$ Agreement $= 8 4 . 6 \%$ (121/143)

Normal Healthy controls: Samples from 205 normal, healthy controls were tested and six samples were positive for IgG anti-AtherOx assay but negative for IgG anti-cardiolipin using the cut-off established in the initial study. The overall $\%$ agreement with the predicate device is $9 7 . 1 \%$ (199/205).

<table><tr><td rowspan=2 colspan=2>Healthy Controls(N = 205)</td><td rowspan=1 colspan=3>REAADS IgG Anti-Cardiolipin</td></tr><tr><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=3 colspan=1>CorgenixIgG Anti-AtherOx</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>6</td></tr><tr><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>199</td><td rowspan=1 colspan=1>199</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>205</td><td rowspan=1 colspan=1>205</td></tr></table>

Rheumatoid arthritis: Serum samples from 99 rheumatoid arthritis patients were tested on the IgG Anti-Athe $\mathrm { \nabla { O X ^ { T M } } }$ Test Kit and the REAADS IgG AntiCardiolipin Test. The mean IgG value of this population was determined to be $1 6 . 4 \mathrm { G }$ Units. One sample was positive for both device but there were 17 samples positive only with the new device, where $5 8 . 8 \%$ (10/17) were near the cut-off for the new device. For this group of patients, the overall $\%$ agreement is $8 2 . 8 \%$ (82/99).

<table><tr><td rowspan=2 colspan=2>Rheumatoid Arthritis(N = 99)</td><td rowspan=1 colspan=3>REAADS IgG Anti-Cardiolipin</td></tr><tr><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=3 colspan=1>CorgenixIgG Anti-AtherOx</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>17</td><td rowspan=1 colspan=1>18</td></tr><tr><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>81</td><td rowspan=1 colspan=1>81</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>98</td><td rowspan=1 colspan=1>99</td></tr></table>

A summary of all samples tested in the method comparison study is as follows:

<table><tr><td rowspan=2 colspan=2>All Subjects(N = 447)</td><td rowspan=1 colspan=3>REAADS IgG Anti-Cardiolipin</td></tr><tr><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=3 colspan=1>CorgenixIgG Anti-AtherOx</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>39</td><td rowspan=1 colspan=1>59</td></tr><tr><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>382</td><td rowspan=1 colspan=1>388</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>26</td><td rowspan=1 colspan=1>421</td><td rowspan=1 colspan=1>447</td></tr></table>

Positive Percent Agreement $= 7 6 . 9 \%$ (20/26) Negative Percent Agreement $= 9 0 . 7 \%$ (382/421) Overall $\%$ Agreement $= 8 9 . 9 \%$ (404/447)

b. Matrix comparison: Both assays use serum as the matrix.

3. Clinical studies:

a. Clinical Sensitivity and Specificity: The tables below show the same samples from the above comparison data, but presented according to the diagnosis.

<table><tr><td colspan="1" rowspan="1">Disease state</td><td colspan="1" rowspan="1">N</td><td colspan="1" rowspan="1">Corgenix anti-AtherOx% positive</td></tr><tr><td colspan="3" rowspan="1">SLE + Secondary APS</td></tr><tr><td colspan="1" rowspan="1">Preg. Morbidity</td><td colspan="1" rowspan="1">42</td><td colspan="1" rowspan="1">28.6% (12/42)</td></tr><tr><td colspan="1" rowspan="1">Atrial thrombosis</td><td colspan="1" rowspan="1">37</td><td colspan="1" rowspan="1">32.4% (12/37)</td></tr><tr><td colspan="1" rowspan="1">Venous thrombosis</td><td colspan="1" rowspan="1">15</td><td colspan="1" rowspan="1">6.7% (1/15)</td></tr><tr><td colspan="1" rowspan="1">Total</td><td colspan="1" rowspan="1">94</td><td colspan="1" rowspan="1">26.6% (25/94)</td></tr><tr><td colspan="3" rowspan="1">No APS</td></tr><tr><td colspan="1" rowspan="1">Rheumatoid Arthritis (RA)</td><td colspan="1" rowspan="1">99</td><td colspan="1" rowspan="1">18.2% (18/99)</td></tr><tr><td colspan="1" rowspan="1">SLE (no secondary APS)</td><td colspan="1" rowspan="1">19</td><td colspan="1" rowspan="1">5.3% (1/19)</td></tr><tr><td colspan="1" rowspan="1">SLE (APS status unknown)</td><td colspan="1" rowspan="1">30</td><td colspan="1" rowspan="1">26.7% (8/30)</td></tr><tr><td colspan="1" rowspan="1">Total</td><td colspan="1" rowspan="1">148</td><td colspan="1" rowspan="1">18.2% (27/148)</td></tr><tr><td colspan="1" rowspan="1">Total number of patient samples</td><td colspan="2" rowspan="1">242</td></tr></table>

<table><tr><td rowspan=2 colspan=2></td><td rowspan=1 colspan=3>APS</td></tr><tr><td rowspan=1 colspan=1>(+)</td><td rowspan=1 colspan=1>(-)</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=3 colspan=1>Corgenix IgGAnti-AtherOx</td><td rowspan=1 colspan=1>(+)</td><td rowspan=1 colspan=1>25</td><td rowspan=1 colspan=1>27</td><td rowspan=1 colspan=1>52</td></tr><tr><td rowspan=1 colspan=1>(-)</td><td rowspan=1 colspan=1>69</td><td rowspan=1 colspan=1>121</td><td rowspan=1 colspan=1>190</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>94</td><td rowspan=1 colspan=1>148</td><td rowspan=1 colspan=1>242</td></tr></table>

Sensitivity: $2 6 . 6 \%$ (25/94) Specificity: $8 1 . 8 \%$ (121/148)

4. Clinical cut-off: See Assay cut-off.   
5. Expected values/Reference range: Expected value in the normal population is negative. Six (6) samples were positive by the Corgenix IgG Anti-Athe $\mathbf { \nabla } \cdot \mathrm { O x } ^ { \mathrm { T M } }$ assay.

N. Proposed Labeling:

The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

# O. Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.